Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Akorn, Inc. (NASDAQ: AKRX).

Full DD Report for AKRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: AKRX)

SA Interview: Event-Driven Investing With Donostia
Feature interview Donostia is an analyst at an event-driven hedge fund who focuses on long/short ideas across the capital structure. We emailed with Donostia about how regulators have changed their definition of competition as part of antitrust review, how merger arb returns should be me...
Source: SeekingAlpha
Date: May, 13 2018 07:30
Free Daily Technical Summary Reports on Horizon Pharma and Three More Generic Drugs Stocks
Stock Research Monitor: AKRX, COLL, and LPCN LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want a free Stock Review on HZNP sign up now at www.wallstequities.com/registration . WallStEquities.com features the Generic Drugs market, which can be segmented into biosimilars, simple ...
Source: ACCESSWIRE IA
Date: May, 11 2018 07:00
DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - AKRX
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Akorn, Inc. ("Akorn") (NASDAQ: AKRX) between March 1, 2017 and February 26, 2018 . You are her...
Source: ACCESSWIRE IA
Date: May, 07 2018 12:20
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
LOS ANGELES, CA / ACCESSWIRE / May 7, 2018 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX ) for violations of §§10(b) and 20(a) of the Securities Ex...
Source: ACCESSWIRE IA
Date: May, 07 2018 11:05
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX) and certain of its officers, on behalf of shareholders who purchased Akorn securities...
Source: ACCESSWIRE IA
Date: May, 07 2018 10:27
DEADLINE MONDAY: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (AKRX)
NEW YORK, NY / ACCESSWIRE / May 4, 2018 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akorn, Inc. (NASDAQ: AKRX) who purchased shares between March 1, 2017 and February 26, 2018 . The action, which was filed in the United States D...
Source: ACCESSWIRE IA
Date: May, 04 2018 14:00
Pawar Law: Important May 7, 2018 Lead Plaintiff Deadline in Akorn, Inc. Class Action- AKRX
NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Pawar Law Group reminds shareholders who purchased shares of Akorn, Inc. (NASDAQ: AKRX) from March 1, 2017 through February 26, 2018, both dates inclusive ("Class Period") of the important May 7, 2018 lead plaintiff deadline in the class action. The ...
Source: ACCESSWIRE IA
Date: May, 04 2018 10:30
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018
NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX) and certain of its officers, on behalf of shareholders who purchased Akorn securities...
Source: ACCESSWIRE IA
Date: May, 04 2018 10:07
Your Daily Pharma Scoop: Achaogen Mixed Ad Com, Esperion Mixed Results, InVivo Up On Old Data
Analysis focus: AKAO So, the FDA Ad Com finally backed Achaogen’s (AKAO) plazomicin! While that is good that the committee voted 15-0 (1 abstain) in favor of the cUTI indication, it is not so good that they also voted 11-4 (1 abstain) that that the the data failed to provide subst...
Source: SeekingAlpha
Date: May, 04 2018 08:01
MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
LOS ANGELES, CA / ACCESSWIRE / May 3, 2018 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX ) for violations of §§10(b) and 20(a) of the Securities Ex...
Source: ACCESSWIRE IA
Date: May, 03 2018 12:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1714.0114.2414.2513.8052,310,059
2017-06-2033.4833.4133.6233.381,129,667
2017-06-1933.5233.4533.5433.401,646,056
2017-06-1633.4633.4833.5433.381,842,377
2017-06-1533.3733.4533.4833.321,176,397

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17318,429581,94854.7178Short
2018-08-16202,999397,66051.0484Short
2018-08-15176,183309,23856.9733Short
2018-08-14156,222302,34351.6705Short
2018-08-1382,227129,47063.5105Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AKRX.


About Akorn, Inc. (NASDAQ: AKRX)

Logo for Akorn, Inc. (NASDAQ: AKRX)

Not available

 

Contact Information

 

 

Current Management

  • Bernard J. Pothast / CFO

Current Share Structure

  • Market Cap: $1,784,935,264 - 05/14/2018
  • Issue and Outstanding: 125,258,615 - 04/26/2018

 


Recent Filings from (NASDAQ: AKRX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 28 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 14 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 14 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: AKRX)

Daily Technical Chart for (NASDAQ: AKRX)


Stay tuned for daily updates and more on (NASDAQ: AKRX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AKRX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AKRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AKRX and does not buy, sell, or trade any shares of AKRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/